Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&JInvestors Business Daily • 02/23/26
Gilead pays $7.8bn to take full control of promising multiple myeloma therapyProactive Investors • 02/23/26
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyoutMarket Watch • 02/23/26
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-celBusiness Wire • 02/23/26
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-celBusiness Wire • 02/23/26
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding OptionsBusiness Wire • 02/17/26
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 02/13/26
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power SalesZacks Investment Research • 02/11/26
Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/11/26
Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/10/26